BioSpace News Archive

Key components driving the global safety needles market are ascend in accentuation on counteractive action of needlestick wounds and broad utilization of prefilled syringes.

Platinum-based drugs contain coordinated complexes of platinum. These are widely used in the treatment of cancer as chemotherapeutic agents.

The global CAR-T cell therapy market is set to chart stellar growth owing to an impressive CAGR between 2018 and 2028.

Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company’s (NYSE: LLY) 40-week SURPASS-2 clinical trial.

Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and venous disorders, announced the appointment of Ali Bauerlein to its Board of Directors.

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced today announced that the Company’s management will participate and present a corporate overview at the H.C. Wainwright Global Life Sciences Conference,

Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced NX-13, the Company’s first-in-class novel, orally administered therapeutic candidate for the treatment of inflammatory bowel disease (IBD), has successfully met all primary and secondary endpoints in a Phase 1 study.

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, announced that Michael F. Cola, President and Chief Executive Officer, will present at two upcoming virtual conferences.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease,